AFMD: Rega marang dodolan Affimed NV
Affimed (AFMD) revenue valuation reflects a trend with the metric currently at 3.10. Current cash reserves at Affimed allow for the systematic funding of immuno-oncology developments. Capital expenditure efficiency is achieved by outsourcing late-stage production to external contractors. Meanwhile, the leadership's scientific expertise in innate immune activation facilitates the formation of strategic alliances with pharma behemoths.
Rincian analitis perusahaan Affimed (AFMD)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Utang Agregat marang Ekuitas Affimed|AFMD - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal affimed.com|AFMD - Utang perusahaan|Utang marang nilai buku Affimed Therapeutics|AFMD - Utang jangka dawa perusahaan|Utang jangka cendhak Affimed|Rasio likuiditas darurat affimed.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
AFMD - Bathi resik|Proyeksi bathi mangsa ngarep Affimed|AFMD - Pangali P/E|Rasio rega marang bathi sing dikarepake affimed.com|AFMD - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Affimed Therapeutics|AFMD - Bathi operasional EBITDA|Bathi saben saham sajrone 12 wulan pungkasan Affimed|AFMD - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan affimed.com|AFMD - Wutah bathi ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Affimed
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:AFMD (Affimed NV)
Affimed monetizes its biotechnological developments through long-term licensing agreements with pharmaceutical corporations. An analysis of the price-to-sales ratio allows for a comparison of market capitalization against the volume of these inflows, determining how much investors are willing to pay per unit of the company's revenue, which serves as a key indicator of the asset's fundamental overvaluation or undervaluation over the long term.
Perusahaan pesaing
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|PTGX - Multiplikator P/S|IMVT: Multiplikator P/S|Rasio rega marang dodolan KNSA (kiniksa.com)|GRFS (Grifols) - Multiplikator P/S|Adaptive Biotech - Rasio rega marang dodolan|Multiplikator P/S CLDX|Koefisien rega marang pendapatan Aurinia Corp|Rasio rega marang pendapatan BioCryst BCRX|VERA - Kapitalisasi marang pendapatan|Dianthus Therapeutics, Inc. - Multiplikator P/S|Rega marang dodolan Pharvaris NV|ABCL: Multiplikator P/S|Rasio kapitalisasi marang pendapatan TRML|PGEN (Precigen, Inc.) - Multiplikator P/S|Multiplikator P/S pharming.com|Multiplikator P/S NKTR|UPB: Rasio rega marang dodolan|Rasio rega marang pendapatan Zenas Biopharma, Inc. ZBIO|IMNM - Kapitalisasi marang pendapatan|Gossamer Bio, Inc. - Multiplikator P/S|KALV (kalvista.com) - Rasio kapitalisasi marang pendapatan|Septerna (SEPN) - Rasio rega marang pendapatan|Rasio rega marang dodolan PVLA (Pieris Pharma)|SVRA (Savara Corp) - Multiplikator P/S|RIGL: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ANAB|Multiplikator P/S astriatx.com (ATXS)|Rasio rega marang pendapatan enGene ENGN|Rasio kapitalisasi pasar marang pendapatan RAPT|JBIO - Rasio rega marang pendapatan|Aclaris Therapeutics, Inc (ACRS) - Kapitalisasi marang pendapatan|KYTX: Multiplikator P/S|tizianalifesciences.com (TLSA) - Multiplikator P/S|Kapitalisasi marang pendapatan CABA|VTYX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S THTX|Koefisien rega marang pendapatan Avalo Therapeutics Inc|Rasio rega marang pendapatan Eledon Pharmaceuticals ELDN|AGEN - Kapitalisasi marang pendapatan|CLYM - Rasio rega marang pendapatan|Zura Bio Ltd (ZURA) - Kapitalisasi marang pendapatan|ATYR (aTyr) - Kapitalisasi marang pendapatan|Adagene Inc. (ADAG) - Multiplikator P/S|Rasio rega marang pendapatan ImageneBio|Rasio kapitalisasi marang pendapatan STTK (Shattuck Therapeutics)|Multiplikator P/S EQ|CNTB - Rega marang dodolan|Multiplikator P/S IMUX (Immunic)|Multiplikator P/S Atara Biotherapeutics, Inc. ATRA|InflaRx GmbH - Multiplikator P/S|Rasio rega marang dodolan XFOR|ACET: Multiplikator P/S|Rasio rega marang dodolan CELU (Celularity)|INMB (INmune Bio Corp) - Multiplikator P/S|Barinthus Biotherapeutics Corp (BRNS) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Kezar Life Sciences (KZR)|Kapitalisasi marang pendapatan sabbiotherapeutics.com SABS|Multiplikator P/S AKTX (Akari Therapeutics Plc)|Enlivex Therapeutics Ltd (ENLV) - Rega marang dodolan|Q32 Bio Corp - Multiplikator P/S|GOVX (GeoVax Corp) - Rasio kapitalisasi marang pendapatan|EDSA: Multiplikator P/S|ibioinc.com (IBIO) - Multiplikator P/S|CARM (Carisma Therapeutics Inc) - Multiplikator P/S|XTL Biopharmaceuticals Ltd - Rasio rega marang dodolan|Rasio rega marang pendapatan Bolt Biotherapeutics (BOLT)|Kapitalisasi marang pendapatan hcwbiologics.com HCWB|Multiplikator P/S APVO (Aptevo Therapeutics Inc.)|AIM: Rasio kapitalisasi marang pendapatan|ADTX - Rasio rega marang pendapatan|Rasio rega marang dodolan GRI|XRTX: Multiplikator P/S|Vyome Therapeutics - Rasio kapitalisasi pasar marang pendapatan|REVB (Revelation Biosciences) - Multiplikator P/S|Multiplikator P/S indaptusrx.com|Rasio rega marang pendapatan Scinai Immunotherapeutics Ltd. (SCNI)|CALI (calcimedica.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Allakos ALLK|HOOK - Kapitalisasi marang pendapatan|IGM Bio - Multiplikator P/S|ITOS - Multiplikator P/S|OCEA (Ocean Biomedical) - Kapitalisasi marang pendapatan|TC BioPharm (Holdings) Plc - Rasio kapitalisasi pasar marang pendapatan|THRD (Third Harmonic Bio, Inc) - Multiplikator P/S
